FUNCTION OF LYMPHOCYTE B1 INTEGRINS
FUNCTION OF LYMPHOCYTE B1 INTEGRINS
批准号:
2184568
负责人:
YOSHIKAZU TAKADA
金额:
$21.5万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-07-01 至 1996-06-30
关键词:
CHO cells Peyer's patches asparagine blood donor cell adhesion molecules cell cell interaction collagen extracellular matrix fibronectins gene expression human subject integrins laminin ligands lymphocyte molecular cloning nucleic acid sequence plasmids platelet aggregation platelet disorder protein sequence receptor binding synthetic peptide thrombasthenia transfection tyrosine vascular endothelium
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Integrins play important roles in immune response, lymphocyte targeting,
and regulation of gene expression. Recently, alpha3 and alpha4 chains of
integrins VLA3 and 4 were cloned and sequenced. VLA3 is a fibronectin
(FN)/collagen/laminin receptor. VLA4 is a) a FN receptor, b) receptor for
vascular cell adhesion molecule-1 (VCAM-1) which is expressed on an
activated endothelial cell surface, and c) a homing receptor of lymphocytes
for Peyer's patch. VLA5 is a classical FN receptor which recognizes the
RGD sequence of a FN cell binding domain. Each integrin plays a role in
lymphocyte function, and therefore is a potential diagnostic and
therapeutic target in immunologic diseases.
To elucidate the mechanism of VLA3-5/ligands interaction, it is proposed 1)
to identify the VLA3 binding sites in collagen, laminin and FN molecules by
using the recombinant VLA3 expressed in transfected cells and ligand
fragments or synthetic peptides, 2) to identify candidate ligand binding
sites on VLA3-5 molecules by chemical cross-linking of the labeled
synthetic peptides from the identified binding sites in the ligand
molecules (e.g. CS-1 peptide for VLA4, RGD containing peptide for VLA5) to
integrins, and 3) to examine a) the effects of the mutation of the
identified ligand binding sites, b) the effects of the introduction of the
function inhibiting mutations in beta2 or beta3 integrin in patients [e.g.
Glanzmann's thrombasthenia (Asp 119 to Tyr in beta3 chain)] into the
corresponding site of beta1 integrin on the functions of the VLA3-5. In
order to accomplish the proposed work the stably transfected CHO cell lines
which express a large quantity of recombinant VLA3 or VLA4 species on the
surface will be established (VLA5 overproducing cells are already
available).
These experiments will analyze the common and specific mechanisms of VLA3-
5/ligand interaction. Peptides which modify these interactions might
modulate the targeting and function of lymphocytes, monocytes and other
cells involved in the pathogenesis of the immunologic diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
-
批准号:8357281
-
项目类别:
-
资助金额:$2.52万
-
财政年份:2011
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
-
批准号:8172556
-
项目类别:
-
资助金额:$3.8万
-
财政年份:2010
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
-
批准号:7653318
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2009
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
-
批准号:8015202
-
项目类别:
-
资助金额:$30.84万
-
财政年份:2009
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
-
批准号:7959054
-
项目类别:
-
资助金额:$3.56万
-
财政年份:2009
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
-
批准号:7771748
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2009
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
-
批准号:8204768
-
项目类别:
-
资助金额:$30.94万
-
财政年份:2009
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
-
批准号:7715651
-
项目类别:
-
资助金额:$2.71万
-
财政年份:2008
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Integrins and the proinflammatory phospholipase A2
-
批准号:7142872
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2006
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Integrins and the proinflammatory phospholipase A2
-
批准号:7282664
-
项目类别:
-
资助金额:$21.18万
-
财政年份:2006
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
Characterization of Targeting Ligands-Integrin Interaction and in vitro targeting
-
批准号:6934086
-
项目类别:
-
资助金额:$11.05万
-
财政年份:2005
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS
-
批准号:2692217
-
项目类别:
-
资助金额:$27.71万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
ALPHA2 BETA1 INTEGRIN (VLA2) LIGAND INTERACTION
-
批准号:2022763
-
项目类别:
-
资助金额:$23.4万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS
-
批准号:6490063
-
项目类别:
-
资助金额:$30.51万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
ALPHA2 BETA1 INTEGRIN (VLA2) LIGAND INTERACTION
-
批准号:2187465
-
项目类别:
-
资助金额:$22.52万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS
-
批准号:6138473
-
项目类别:
-
资助金额:$27.4万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
ALPHA2 BETA1 INTEGRIN (VLA2) LIGAND INTERACTION
-
批准号:2634724
-
项目类别:
-
资助金额:$24.33万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS
-
批准号:6342877
-
项目类别:
-
资助金额:$28.21万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
ALPHA2 BETA1 INTEGRIN (VLA2) LIGAND INTERACTION
-
批准号:2187464
-
项目类别:
-
资助金额:$21.05万
-
财政年份:1995
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
LIGAND BINDING FUNCTION OF BETA INTEGRINS
-
批准号:2184570
-
项目类别:
-
资助金额:$24.51万
-
财政年份:1991
-
负责人:YOSHIKAZU TAKADA
-
依托单位:
海外基金